Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSmith & Nephew Regulatory News (SN.)

Share Price Information for Smith & Nephew (SN.)

Share Price is delayed by 15 minutes
Get Live Data
1,136.50    0.00 (0.00%)
Bid:
1,060.00
Ask:
0.00
Spread: 81.50 (7.689%)
Market Cap: £9.65b
SN. Live PriceLast checked at - London Stock Exchange

Intraday Smith & Nephew Share Chart

Director/PDMR Shareholding

21 May 2025 15:00

RNS Number : 6489J
Smith & Nephew Plc
21 May 2025
 

SMITH & NEPHEW PLC

 

21 May 2025

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

This announcement is made in accordance with the UK Market Abuse Regulation (Regulation (EU) 596/2014, as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018).

 

1. VESTING OF SHARE AWARDS UNDER THE GLOBAL SHARE PLAN 2020

 

On 20 May 2025, the Company received notification of the following transactions in US$0.20 ordinary shares (the "Shares") in Smith & Nephew plc (the "Company") following the vesting of awards under the Smith & Nephew Global Share Plan 2020.

 

All figures in these columns are stated to 6 decimal places where applicable.

 

i. VESTING OF PERFORMANCE SHARE PLAN AWARDS MADE UNDER THE SMITH & NEPHEW GLOBAL SHARE PLAN 2020

 

The awards were granted under the Global Share Plan 2020 and vested on 20 May 2025 at 59.35% of target. A number of Shares were sold to cover taxation obligations arising on the vesting of the awards as detailed in the table below. The number of Shares acquired includes the dividend equivalent Shares which the participant received on the vested Shares. The table below sets out the number of shares under award which vested. The remaining shares under award have lapsed.

 

Reason for the notification

Initial notification /Amendment

Initial notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Name

Smith & Nephew plc

LEI

213800ZTMDN8S67S1H61

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

Description of the financial instrument, type of instrument

 

Smith & Nephew plc ordinary shares of USD 0.20 each

 

Identification code

ISIN: GB0009223206

Nature of the transaction

Vesting on 20 May 2025 of Performance Share Plan awards granted under the Smith & Nephew Global Share Plan 2020, and subsequent sale of shares to cover tax liability

Date of Transaction

2025 - 05 - 20

Place of Transaction

London Stock Exchange (XLON)

 

Name

(Position)

 

Status

Price (£)

Volume

Aggregated information

Deepak Nath

(Chief Executive Officer)

PDMR

10.875359

83,938 (of which 34,477 were sold and 49,461 were retained)

N/A Single Transaction

 

 

ii. VESTING OF CONDITIONAL AWARDS MADE UNDER THE SMITH & NEPHEW GLOBAL SHARE PLAN 2020

 

The awards were granted under the Global Share Plan 2020 and vested on 20 May 2025. A number of Shares were sold to cover taxation obligations arising on the vesting of the awards as detailed in the table below.

 

The following relates to individuals included in the below notification:

 

Reason for the notification

Initial notification /Amendment

Initial notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Name

Smith & Nephew plc

LEI

213800ZTMDN8S67S1H61

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

Description of the financial instrument, type of instrument

 

Smith & Nephew plc ordinary shares of USD 0.20 each

 

Identification code

ISIN: GB0009223206

Nature of the transaction

Vesting on 20 May 2025 of Conditional Share awards granted under the Smith & Nephew Global Share Plan 2020, and subsequent sale of shares to cover tax liability

Date of Transaction

2025 - 05 - 20

Place of Transaction

London Stock Exchange (XLON)

 

 

Name

(Position)

 

Status

Price (£)

Volume

Aggregated information

Craig Gaffin

(President, Global Orthopaedics)

PDMR

10.875359

 

1,551 (of which 379 were sold and 1,172 were retained)

N/A Single Transaction

Elga Lohler

(Chief HR Officer)

PDMR

10.875359

20,174 (of which 8,026 were sold and 12,148 were retained)

N/A Single Transaction

Vasant Padmanabhan

(President Research & Development and ENT)

PDMR

10.875359

19,626 (of which 8,708 were sold and 10,918 were retained)

N/A Single Transaction

Rohit Kashyap

(President, Advanced Wound Management and Global Commercial Operations)

PDMR

10.875359

11,949 (of which 2,920 were sold and 9,029 retained)

N/A Single Transaction

 

 

 

Philip Horner

Deputy Company Secretary

Smith & Nephew plc

 

Tel: +44 (0)1923 477100

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHFLFSVETILFIE
Date   Source Headline
19th Aug 20257:00 amRNSTransaction in Own Shares
18th Aug 20257:00 amRNSTransaction in Own Shares
15th Aug 20257:00 amRNSTransaction in Own Shares
14th Aug 20257:00 amRNSTransaction in Own Shares
13th Aug 20255:08 pmRNSDirector/PDMR Shareholding
13th Aug 20257:00 amRNSTransaction in Own Shares
12th Aug 20257:00 amRNSTransaction in Own Shares
11th Aug 20257:00 amRNSTransaction in Own Shares
8th Aug 20257:00 amRNSTransaction in Own Shares
7th Aug 20254:30 pmRNSHolding(s) in Company
7th Aug 20253:15 pmRNSHolding(s) in Company
7th Aug 202510:34 amRNSDirector/PDMR Shareholding
7th Aug 20257:00 amRNSTransaction in Own Shares
6th Aug 20257:00 amRNSTransaction in Own Shares
5th Aug 20257:01 amRNSShare Buyback Programme
5th Aug 20257:00 amRNSHalf-year Report
1st Aug 202510:21 amRNSTotal Voting Rights
21st Jul 202511:51 amRNSNotice of Results
11th Jul 202510:00 amRNSDirector/PDMR Shareholding
1st Jul 20251:30 pmRNSTotal Voting Rights
13th Jun 20257:00 amRNSDirectorate Change
6th Jun 20254:16 pmRNSDirector/PDMR Shareholding
2nd Jun 20252:07 pmRNSTotal Voting Rights
30th May 20251:22 pmRNSDirector/PDMR Shareholding
21st May 20253:00 pmRNSDirector/PDMR Shareholding
14th May 20257:00 amRNSSterling Amount of Dividend
7th May 202511:53 amRNSDirector/PDMR Shareholding
2nd May 202511:30 amRNSDirector/PDMR Shareholding
1st May 202511:27 amRNSTotal Voting Rights
30th Apr 20255:30 pmRNSResult of AGM
30th Apr 20257:00 amRNSSmith+Nephew First Quarter 2025 Trading Update
28th Apr 20251:49 pmRNSHolding(s) in Company
25th Apr 20259:18 amRNSDirectorate Change
22nd Apr 20257:00 amRNSNotice of Results
1st Apr 202512:41 pmRNSTotal Voting Rights
27th Mar 20259:17 amRNSDirector/PDMR Shareholding
27th Mar 20259:12 amRNSDirector/PDMR Shareholding
11th Mar 20253:25 pmRNSDirector/PDMR Shareholding
10th Mar 20252:46 pmRNSAnnual Financial Report
3rd Mar 20252:58 pmRNSTotal Voting Rights
25th Feb 20257:00 amRNSFinal Results
12th Feb 20257:11 amRNSBlock listing Interim Review
6th Feb 20257:00 amRNSNotice of Results
3rd Feb 202510:27 amRNSTotal Voting Rights
14th Jan 20257:00 amRNSDirectorate Change
2nd Jan 202512:51 pmRNSTotal Voting Rights
20th Dec 20249:46 amRNSDirector/PDMR Shareholding
16th Dec 202411:50 amRNSHolding(s) in Company
12th Dec 20249:53 amRNSHolding(s) in Company
11th Dec 20249:03 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.